# CML Treated With Bosutinib After Relapse

> **NCT02445742** · PHASE2 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 30 (actual)

## Conditions studied

- Chronic Myeloblastic Leukaemia

## Interventions

- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT02445742
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-12
- **Final completion:** 2019-06-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445742, "CML Treated With Bosutinib After Relapse". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02445742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*